1. Introduction {#sec1}
===============

Hand-foot-and-mouth disease (HFMD), being caused by a group of enteric viruses including enterovirus 71 (EV71), coxsackievirus A16 (CVA16), and coxsackievirus A10 (CVA10), is currently a serious epidemic in China \[[@B1]\]. HFMD is a common, mild, and self-limiting rash-associated illness in children under the age of 6 but could lead to mortality in large-scale outbreaks. Since first being described in California in 1969, there have been many reports on large EV71 outbreaks all over the world. Generally, severe cases of HFMD were associated with severe neurologic disorders like acute flaccid paralysis, pulmonary edema, myocarditis, and fatal encephalitis \[[@B2]\]. HFMD has already been emerged as an imperative global hazard, not only threatening the health of the children, but also causing tremendous loss and burden to both families and society.

Despite substantial progress that has been made in understanding many aspects of the biology and pathogenesis of HFMD, continuous search for new and more effective agents against HFMD has never been relented as the appropriate vaccines and antiviral drugs remain unavailable \[[@B3]\]. At the present moment, there is still no effective treatment that can work against the disease clinically \[[@B4]\]. Hence, Traditional Chinese Medicine (TCM) that has been proven as excellent alternative remedy against viral infection \[[@B5]\] could be a potential HFMD treatment option. More researches have shown that TCM plays a crucial role in improving the disease progression of HFMD over the past few decades \[[@B6]\]. In addition, extracts of Chinese medicines such as kappa carrageenan \[[@B3]\], geraniin \[[@B4]\], and Kalanchoe gracilis \[[@B7]\] have exerted strong and effective anti-EV71 and anti-CVA16 activities both *in vitro* and *in vivo*. However, since the exact pathogenesis of HFMD and the complex components of effective TCM remain unclear, it is hard to fully understand the mechanism of TCM action in the human body. Thus, the establishment of a more efficient and reliable method to evaluate the remedial effects of TCM on HFMD intervention will be of imminent importance.

The metabolomic approach has focused on studying the endogenous metabolites with low molecular weight in the biological samples. According to our knowledge, the small molecular-sized endogenous metabolites play an important role in the physiological system and represent attractive candidates for better understanding of biological phenotypes \[[@B8]\]. Metabolomics is a newly emerging field in analytical biochemistry other than genomics and proteomics and can be regarded as the endpoint of the "omics" cascade \[[@B9]\]. It aims to characterize and quantify all small metabolites that are related to drug toxicity, disease progression, environmental stimuli, and genetic variations by using nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry (MS) \[[@B10]\]. Several studies have described the metabolomics-based research on TCM, for instance, in our laboratory when investigating pattern differentiation \[[@B11], [@B12]\] and pharmacological mechanisms \[[@B13]\] and in other laboratories performing quality control of Chinese herbs \[[@B14]\]. As metabolomics can readily detect subtle changes in the metabolic network, it is uniquely poised to increase our understanding of HFMD and the related intervention methods.

In the present study based on the liquid chromatography/quadrupole time-of-flight mass spectrometry (LC-Q-TOF-MS) platform, we investigated the serum metabolic characteristics of HFMD to gain more insight of the metabolic perturbations associated with the disease for the first time. Besides, the potential therapeutic effects and the underlying mechanisms were also explored.

2. Materials and Methods {#sec2}
========================

2.1. Chemicals {#sec2.1}
--------------

LC-MS grade acetonitrile and methanol was purchased from Honeywell Burdick and Jackson (Muskegon, USA). Mass Spectroscopic grade formic acid was purchased from Fluka (Buchs, Switzerland). Distilled water was purified "in-house" using a Milli-Q20 system (Millipore; MA, USA). All metabolites standards were obtained from Sigma-Aldrich (MO, USA).

2.2. Sample Collection and Preparation {#sec2.2}
--------------------------------------

Eighteen severe patients with clinical symptoms of HFMD were recruited if they met the Guideline for the Diagnosis and Treatment of HFMD in China (Ministry of Health, 2010) \[[@B15]\] from Beijing YouAn Hospital (China) during September and October, 2010. Additional inclusion criteria were ages 1--13 years and no more than 24 hours after the occurrence of central nervous system symptoms, with any of the following: lethargy and weakness, agitation or irritability, headache, vomiting, limb weakness or acute flaccid paralysis, myoclonic jerks, ataxia, nystagmus, or oculomotor palsies. Patients who have been suffering from neurogenic pulmonary edema or heart or respiratory failure were excluded. All patients were identified as EV71-positive by a diagnostic kit (RT-PCR double Fluorescence Taqman probes, Da An Gene Company Limited, China). The patients were then assigned to combination therapy (with combination of conventional Western medicine and Chinese medicine treatments). Conventional Western medicine treatments included mannitol (0.5--1.0 g/kg) administered IV over a period of 30--40 min for every 4--8 h; glucocorticoid methylprednisolone (1-2 mg/kg/24 h); hydrocortisone (3--5 mg/kg/24 h); dexamethasone (0.2--0.5 mg/kg/24 h); intravenous immunoglobulin (IVIG; 2 g/kg) for 2--5 days. Herb derived compound Andrographolide Sulfonate (called Xiyanping injection), approved for clinical use by State Food and Drug Administration (China), is recommended for the treatment of HFMD. Xiyanping injection was administered as intravenous infusion (5--10 mg/kg/day; in 5% dextrose). The Xiyanping injection used in our study appeared as light yellow to orange clear liquid, which is composed of total andrographolide sulfonate, and manufactured by Jiangxi Qingfeng Pharmaceutical Inc. (GMP certificated). The criteria for the quality of injection procedures were in accordance with the Chinese pharmacopoeia (2010) \[[@B16]\]. The Xiyanping injection treatment was given in combination with conventional Western medicine cocktail for 7--10 days. The average hospital stay of these children was 7.6 days. Venous blood samples were collected in the morning preprandially from HFMD patients (before and 7 days after drug treatment) and age-matched healthy control subjects (*n* = 18). Between HFMD patient and health control group, the difference of age was not significant (*P* = 0.628, *t* test, [Table 1](#tab1){ref-type="table"}). An Institutional Review Board had approved the previous research protocols on human subjects based on ethical and safety considerations prior to the commencement of the study and all participants had provided their informed consent in writing. One hundred *μ*L of the collected serum sample was added to 300 *μ*L methanol, and the mixture was vortexed vigorously for 30 s. After centrifugation at 9562.5 ×g for 10 min at 4°C, the supernatant was stored at −80°C until analysis \[[@B17]\].

2.3. LC-Q-TOF-MS Analysis {#sec2.3}
-------------------------

The LC-Q-TOF-MS analysis was performed by using an Agilent-1200 LC system, which was coupled with an electrospray ionization (ESI) source (Agilent Technologies, Palo Alto, CA, USA) and an Agilent-6520 Q-TOF mass spectrometry. The separation of all samples was performed on an Eclipse plus C18 column (1.8 *μ*m, 2.1 mm × 100 mm, Agilent) with a column temperature being set at 45°C. The flow rate was 400 *μ*L/min, and the mobile phase consisted of ultrapure water with 0.1% formic acid (A) and acetonitrile (B). The following gradient program was used: 0-1 min, 2% B; 1--3 min, 2--20% B; 3--6 min, 20--30% B; 6--11 min, 30--85% B; 11--18 min, washed with 100% B and followed by a reequilibration step of 6 min. The sample injection volume was 2 *μ*L. Mass detection was operated in both positive and negative ion modes with the following setting: drying gas (N~2~) flow rate, 8 L/min; gas temperature, 330°C; pressure of nebulizer gas, 35 psig; Vcap, 4100 V (positive mode) and 3900 V (negative mode); fragmentor, 130 V; skimmer, 65 V; scan range, *m*/*z* 80--1000. MS/MS analysis was acquired under targeted MS/MS mode with collision energy from 10 to 40 V.

2.4. Sequence of Analysis {#sec2.4}
-------------------------

The pooled QC sample was analyzed at the beginning, the end, and randomly through the analytical run to monitor the stability of sequence analysis. The typical batch sequence of serum samples consisted of the consecutive analysis of 1 QC serum sample (at the beginning of the study), followed by 6 unknown serum samples, 1 QC serum sample, before running another 6 unknown serum samples, and so forth. Meanwhile, samples were analyzed in a random order for a normal good practice. An identical sequence was repeated to complete the total set of injections (*n* = 64, including QCs) analyzed in less than 1 day per mode \[[@B18]\].

2.5. Data Analysis {#sec2.5}
------------------

The LC-MS raw data were exported and analyzed by the Agilent Mass Hunter Qualitative Analysis Software (Agilent Technologies, Palo Alto, CA, USA). Before undergoing multivariate analysis, each data was normalized by the total area to correct for the MS response shift due to the long duration between first and last injections. After this modulation, the sum of the ion peak areas within each sample was set to 10,000. Partial least squares discriminant analysis (PLS-DA) and orthogonal partial least square (OPLS) were used for analysis of metabolite profiles. Multivariate analysis was performed by the SIMCA-P software (11th version; Umetrics AB, Umeå, Sweden). Variable importance projection (VIP) was used to select differential metabolites responsible for the intergroup discrimination of each model. Statistical significance was determined by the one-way analysis of variance (ANOVA) using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA), followed by Duncan post hoc tests. *P* values less than 0.05 were considered significant. We obtained information about prediction of candidate metabolites corresponding with these significant *m*/*z* values by searching the biofluid metabolites database. Then, the differential RT-*m*/*z* pairs were identified between two groups by matching with tandem MS fragmentation patterns with reference standards. Relationships between differentially expressed metabolites were investigated in pathway analysis using the Ingenuity Pathway Analysis (IPA) software (Ingenuity, Redwood City, CA).

3. Results {#sec3}
==========

3.1. Sample Repeatability {#sec3.1}
-------------------------

Extracts from six aliquots of a random blood sample were continuously injected to evaluate the repeatability. Five common extracted ion chromatograms (EICs) shared by these injections were selected according to their different chemical polarities and *m*/*z* values. The relative standard derivations (RSDs) of these peaks were 3.29%--14.54% for peak areas and 0.03%--0.96% for retention times.

3.2. System Stability {#sec3.2}
---------------------

The LC-MS system stability for the large-scale sample analysis was demonstrated by the test of pooled QC samples. The principal components analysis (PCA) result shows that QC samples are tight clustered. Moreover, peak areas, retention times, and mass accuracies of five selected EICs in five QC samples also showed good system stability. RSDs of the five peaks were 4.74%--14.18% for peak areas, 0.02%--0.98% for retention times, and 0.10*E*−04%--0.79*E*−04% for mass accuracies. The result indicated that large-scale sample analysis had hardly any effect on the reliability of data.

3.3. Metabolic Comparison Based on OPLS between HFMD and Healthy Control {#sec3.3}
------------------------------------------------------------------------

The difference between HFMD group (patients prior to drug treatment) and healthy control group is our initial focus in this study. To maximize the difference of their metabolic profiles, a sophisticated orthogonal partial least squares projection to latent analysis (OPLS) model was applied. OPLS is a supervised method to pick out discriminating ions \[[@B19]\] that are contributing to the classification of samples and would remove noncorrelated variations contained within spectra \[[@B18]\]. Thus, OPLS was carried out to identify candidate metabolites of HFMD in this study. The OPLS models were validated in the SIMCA-P software by a default 7-round cross-validation procedure with exclusion of 1/7th of the samples from the model in each round in order to avoid the modeling overfitting caused by supervised mathematical methods \[[@B20]\]. The first two components were used in the OPLS model. As shown in Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}, there was a distinguishable classification between the clustering of HFMD group and healthy control group. *Q* ^2^ *Y* and *R* ^2^ *Y* in the OPLS models indicated that the class prediction ability of all models was high, and there was a clear difference being observed between HFMD group and healthy control group. We searched for the presumed molecular formula in the Human Metabolome Database, ChemSpider, KEGG, and some other databases to confirm possible chemical composition. According to the results, a total of the top significant 200 variables (sum of variables detected in both positive mode and negative mode) contributed to the classification of the control, and HFMD groups were selected. Furthermore, among these perturbed variables, 31 endogenous metabolites (16 in positive and 15 in negative) had been identified ([Table 2](#tab2){ref-type="table"}).

3.4. The Network of Identified Metabolites between HFMD Group and Healthy Control Group {#sec3.4}
---------------------------------------------------------------------------------------

Among the 31 identified metabolites, 13 were downregulated in the serum of HFMD patients, while the other 18 were upregulated ([Table 2](#tab2){ref-type="table"}). In order to further understand the correlation between these candidate metabolites, bioinformatics analyses were performed using the IPA software, and these analyses led to the identification of biological association networks. As shown in [Figure 2](#fig2){ref-type="fig"}, it was found that most of the differential metabolites were tightly connected with each other. The established networking functions of HFMD include lipid metabolism, molecular transport, cell signaling, drug metabolism, and small molecule biochemistry, of which all play important roles in the development of HFMD. Meanwhile, the IPA software represented five top canonical pathways, including phospholipases, renin-angiotensin signaling, choline biosynthesis III, phosphatidylcholine biosynthesis I, and TREM1 signaling ([Figure 2](#fig2){ref-type="fig"}).

3.5. Metabolic Profiling Comparison Based on PLS among Healthy Control, HFMD, and Combination Therapy Groups {#sec3.5}
------------------------------------------------------------------------------------------------------------

In order to determine whether the serum metabolome represented in this study could be used to discriminate among different groups, partial least squares discriminant analysis (PLS-DA), a well-established supervised method that has been widely used in metabolomic study \[[@B21]\], was adopted so as to specify the metabolic variations associated with the disease and drug intervention. The first two components were used in the PLS-DA model. As shown in [Figure 3](#fig3){ref-type="fig"}, there was a distinguishable classification between the clustering of HFMD group, CT group (patients 7 days after combination therapy), and control group. Figures [3(a)](#fig3){ref-type="fig"} and [3(b)](#fig3){ref-type="fig"} displayed that separation of the groups could be achieved with the model parameters *R* ^2^ *Y* = 0.875, *Q* ^2^ = 0.710 for positive ESI ion mode and *R* ^2^ *Y* = 0.908, *Q* ^2^ = 0.727 for negative ESI ion mode. *Q* ^2^ *Y* obtained from cross-validation procedure represents the predictive accuracy of the model, and *R* ^2^ *Y* shows how well the model fits to the data. The previous parameters indicated that the two models had good ability to explain the data. Moreover, the results from permutation tests also showed that the two models were not over-fitting and were efficient and reliable (intercepts: *R* ^2^ = 0.167, *Q* ^2^ = −0.172 for positive ion mode data and *R* ^2^ = 0.541, *Q* ^2^ = −0.209 for negative ion mode data). We therefore conclude that HFMD had altered the serum metabolic profiles of patients when compared with healthy individuals, with the perturbations occurring in CT group.

3.6. The Evaluation of Combination Therapy {#sec3.6}
------------------------------------------

By using a similar method, we have identified the significant variables (sum of variables being detected in both positive mode and negative mode) based on the LC-Q-TOF-MS platform, which could contribute to the classification among the groups. As shown in [Table 2](#tab2){ref-type="table"}, the metabolites with dashed area (15 metabolites) were modulated to the normal level in CT group, indicating the potential treatment targets of combination therapy. Associated network functions represented by IPA software include amino acid metabolism, molecular transport, and small molecule biochemistry. IPA also performed five top canonical pathways of these metabolites, including creatine-phosphate biosynthesis, sphingomyelin metabolism, glycine degradation, threonine degradation II, and choline biosynthesis III ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

Human EV71-associated HFMD has become a leading cause of childhood infection in China since 2008. Epidemic and molecular characteristics of HFMD have been examined in many areas of the country \[[@B2]\]. However, clinical and metabolomic characterization of HFMD remains scarce. Metabolomics approach can reveal the profile of endogenous metabolites of low molecular weight in biofluids that are related to disease progression, since it seeks to discover and capitalize on the metabolic derangements that occurred in the body as a result of the mutated genotype being manifested before actual gross phenotypic changes \[[@B22]\]. Many metabolomic efforts have been made to investigate the biomarkers and efficacy evaluation in viral diseases, such as infections by hepatitis C virus (HCV) \[[@B23]\], influenza A virus \[[@B24]\], and HIV-1 \[[@B25]\]. In the present study, the application of metabolomics is well suited for exploration of HFMD.

The compendium that we generated on the changes during the disease processes of HFMD has highlighted a wide variety of molecular and metabolic alterations. More detailed analyses of networks and pathways bring influenced were performed by IPA software. Our data have suggested lipid metabolism as the first important network function of perturbation in HFMD group. From the differentiating metabolites in HFMD, evident alteration in lipid metabolism was observed in HFMD patients following EV71 infection. This finding in fact echoes with another similar work at the proteomic level \[[@B26]\]. Lipid metabolism can be affected in a variety of ways during viral infection, whereas the major lipid changes involve triglycerides, free fatty acids, and ketone bodies, and so on \[[@B27]\]. Studies have demonstrated the relationship between HIV \[[@B28]\], HCV \[[@B29]--[@B31]\], and lipid metabolism, with evaluation of the role of interventions during dyslipidemia. Concomitantly, IPA had generated three related pathways, namely, phospholipases, choline biosynthesis III, and phosphatidylcholine biosynthesis I, which provides direct evidence in the perturbation of lipid metabolism in HFMD. These interrelated pathways implicate that lipid metabolism may be influenced by virus infection. Furthermore, we mainly focused on evaluating individual candidate metabolites during the analysis of lipid metabolism. We observed significantly lower levels of diacylglycerol (DAG) in HFMD patients when compared with those in the healthy control group. DAG is a versatile molecule that participates as substrate in the synthesis of structural and energetic lipids. DAG in lipid droplets from cytoplasm liver cells is associated with insulin resistance in nondiabetic obese human \[[@B32]\]. The termination of DAG signaling by DAG kinases can lead to inhibition of antiviral cytokine production. HIV-1 virus gene expression can be induced by DAG synthesized on a five-member ring platform \[[@B33]\]. This finding might well supplement the pathogenesis of HFMD. Nonetheless, phosphatidylethanolamine (PE) level was found to be decreased in HFMD patients. As a major component in the mammalian plasma membrane, PE is mainly present in the inner leaflet of the membrane bilayer in viable and typical mammalian cells. PE is likely to be a versatile chemical species that plays certain role in the regulation of defined biological and physiological activities \[[@B34]\]. Choline, the basic constituent of lecithin that is found in many plants and animal organs, is up-regulated in HFMD patients. It is essential as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and also in lipid metabolism \[[@B35]\]. Nevertheless, alterations of the cerebral choline can be observed in HCV-infection patients \[[@B36], [@B37]\]. Altogether, the altered lipid metabolite may be a sign of HFMD and reflect the abnormal lipid metabolism status in HFMD patients. Our results could provide a hint for further understanding of the role of lipid metabolism in the pathogenesis of HFMD.

From the signal transduction perspective, renin-angiotensin signaling is closely related. It is well known that renin-angiotensin proteins are key regulators of other signaling cascades, controlling many biological processes such as proliferation, differentiation, and apoptosis \[[@B38]\]. Renin-angiotensin signaling could be potential drug targets to determine the appropriate therapeutic intervention of HFMD. Nevertheless, additional prospective work is needed to investigate the precise mechanism.

It is of interest to note that inflammatory reactions were found to be dysregulated in HFMD patients. It has been considered that inflammation plays an important role during the HFMD process. The milder HFMD cases presented systemic inflammatory response syndrome status in clinical trials \[[@B39]\]. Moreover, patients with central nervous system diseases were found to have acute inflammation of the grey matter at the brain stem \[[@B40]\]. In a basic research, investigators had identified that human P-selectin glycoprotein ligand-1 (PSGL-1; CD162), a sialomucin membrane protein expressed on leukocytes, may play a major role in early stages of inflammation by interacting with selections and chemokines, as a functional receptor for EV71 \[[@B41]\]. Another report also indicated that massive induction of proinflammatory cytokines is responsible for the pathogenicity of EV71 \[[@B42]\]. Urocanic is a breakdown (deamination) product of histidine. In the liver, urocanic acid (UCA) is an intermediate in the conversion of histidine to glutamic acid, whereas in the epidermis, it accumulates and may be both a UV protectant and an immunoregulator \[[@B43]\]. *cis*-UCA can increase cytokine protein production including that of TNF-alpha, IL-6, and IL-8 in a dose-dependent manner \[[@B44]\]. Prostaglandin E~2~ (PGE~2~) is the most common and biologically active prostanoid among mammalian prostaglandins, which has been traditionally regarded as a mediator of immune inflammation \[[@B45]\]. It is interesting that PG-endoperoxide synthase-2 is dramatically induced by *cis*-UCA, resulting in an enhanced secretion of PGE~2~. A relatively high level of UCA, together with PGE~2~, was concurrently found in the HFMD group. These results suggest that the inflammation-related processes in HFMD may be largely perturbed.

HFMD has multiple alternative pathogenic pathways that lead to a particular pathophysiological state, with a wide range of resulting phenotypes. Thus, it provides a significant treatment venture in clinical practice. In this study, we performed combination therapy to determine metabolic changes in HFMD patients. Among 31 HFMD-related metabolites, 15 metabolites were reversed to the level of the health control group, suggesting that the combination therapy has a positive impact on repairing the abnormal metabolic profiles in HFMD. In CT group, the altered pathways include amino acid metabolism (threonine degradation II and glycine degradation) and lipid metabolism (creatine-phosphate biosynthesis, sphingomyelin metabolism, and choline biosynthesis III) ([Figure 4](#fig4){ref-type="fig"}). Amino acid metabolism, especially that of threonine degradation II, glycine degradation being addressed by IPA, is involved in the modulation process of combination therapy based on results from this study. In agreement with previous observation, the amino acid metabolism in patients with hepatitis B virus (HBV) infection is significantly changed \[[@B46]\]. Conserved glycine 33 residue in flexible domain I of HCV core protein is critical for its virulent activity \[[@B47]\]. A previous study has demonstrated that HBV E-antigen physically associates with receptor interaction serine/threonine protein kinase 2 \[[@B48]\]. As a result, our data are consistent with the phenomenon on the interference of glycine and threonine metabolism in viral diseases. We therefore believe that the primary regulatory targets of combination therapy involve modulation of amino acid metabolism. Interestingly, the related pathway of lipid metabolism again showed important role in the regulation of HFMD in CT group, consistent well with the before mentioned. Manipulation of these pathways could aim at the prime targets in successful HFMD therapy in CT group.

5. Conclusions {#sec5}
==============

In summary, a metabolomic approach based on LC-Q-TOF-MS platform was employed to study the metabolic characteristics between HFMD patients and healthy individuals, as well as combination therapy interventions. A clear separation between HFMD patients and healthy subjects was achieved. As a result, 31 endogenous metabolites showed marked perturbation in HFMD patients. We also observed a number of important pathway perturbations in HFMD patients in association with lipid metabolism and inflammation reaction, and so forth. Combination therapy shows positive modulation in HFMD patients in different pathway. Metabolomic technique was deemed useful in the exploration of the complex metabolic states of HFMD, which can also provide a theoretical basis for the prevention and treatment of the disease.
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![OPLS score of healthy control group and HFMD group. The score plot showed that levels of markers in serum of healthy control and HFMD patients were different. (a) Positive ion mode (*k* = 11001, *n* = 36, *R* ^2^ *Y* = 0.985, *R* ^2^ *X* = 0.321, *Q* ^2^ = 0.947, *A* = 1 + 1). (b) Negative ion mode (*k* = 11700, *n* = 36, *R* ^2^ *Y* = 0.986, *R* ^2^ *X* = 0.263, *Q* ^2^ = 0.931, *A* = 1 + 1). Each point represents an individual sample. (Left side, ▲) Samples from HFMD patients. (Right side, ▲) Samples from healthy controls.](ECAM2013-647452.001){#fig1}

![Top five significant molecular networks of HFMD related metabolites merged by IPA. Metabolites are represented as nodes, and the biological relationship between two nodes is represented as a line. Note that the colored symbols represent metabolites that occur in our data, while the transparent entries are molecules from the Ingenuity Knowledge Database. Red symbols represent upregulated metabolites in HFMD patients; green symbols represent downregulated metabolites in HFMD patients. Solid lines between molecules indicate direct physical relationship between molecules; dotted lines indicate indirect functional relationships.](ECAM2013-647452.002){#fig2}

![PLS-DA score plots based on the data from the healthy controls and the HFMD patients. (a) PLS-DA score plots under positive ESI ion mode. (b) PLS-DA score plots under negative ESI ion mode. The black square: healthy control group; the red circle: HFMD group; the blue diamond: combination therapy group.](ECAM2013-647452.003){#fig3}

![Significant molecular network of combination therapy related metabolites. Metabolites are represented as nodes, and the biological relationship between two nodes is represented as a line. Note that the colored symbols represent metabolites that occur in our data, while the transparent entries are molecules from the Ingenuity Knowledge Database. Red symbols represent up-regulated metabolites in HFMD patients after combination therapy; green symbols represent down-regulated metabolites in HFMD patients after combination therapy. Solid lines between molecules indicate direct physical relationship between molecules; dotted lines indicate indirect functional relationships. The yellow dashed area denotes the related pathway.](ECAM2013-647452.004){#fig4}

###### 

Basic feature of HFMD group and healthy control group.

  Group             Number (*n*)   Gender (*n*)   Age (month)^a^   
  ----------------- -------------- -------------- ---------------- -------------
  Healthy control   18             13             5                27.1 ± 10.9
  HFMD              18             11             7                28.9 ± 11.6

^a^Data are expressed as mean ± SD.

###### 

Identified markers between healthy control and HFMD.

  Mode      R.T (min)   Exact mass         Formula                                         Compound (Resource)                            Significance/fold change                
  --------- ----------- ------------------ ----------------------------------------------- ---------------------------------------------- -------------------------- ------------ ------------
            1.8         145.1103           C~7~H~15~NO~2~                                  Acetylcholine (HMDB)                           \*\*/ 1.48                 \*\*/ 0.65   \*\*/ 0.77
            2.5         202.1205           C~10~H~18~O~4~                                  Sebacic acid (HMDB)                            \*\*/ 1.58                 \*\*/ 0.67   N.S
            2.6         90.0317            C~3~H~6~O~3~                                    Lactic acid (HMDB)                             \*\*/ 13.4                 N.S          \*\*/ 13.4
            3.6         258.0141           C~6~H~11~O~9~P                                  2-Keto-3-deoxy-6-phosphogluconic acid (HMDB)   \*\*/ 5.55                 \*\*/ 0.12   N.S
            3.7         247.0246           C~8~H~10~NO~6~P                                 Pyridoxal phosphate (HMDB)                     \*\*/ 5.23                 \*\*/ 0.31   N.S
            6.0         219.1107           C~9~H~17~NO~5~                                  D-Pantothenic acid (HMDB)                      \*\*/ 0.47                 \*\*/ 2.28   N.S
            6.2         138.0429           C~6~H~6~N~2~O~2~                                Urocanic acid (HMDB)                           \*\*/ ∞                    N.S          \*\*/ ∞
  ESI (+)   10.1        180.0634           C~6~H~12~O~6~                                   beta-D-Glucose (HMDB)                          \*\*/ 0.38                 N.S          \*\*/ 0.37
  13.7      519.3325    C~26~H~50~NO~7~P   1-18:2(9Z,12Z) Lysophosphatidylcholine (HMDB)   \*\*/ 0.49                                     \*\*/ 1.84                 N.S          
            12.71       169.0504           C~4~H~12~NO~4~P                                 Phosphorylcholine (HMDB)                       \*\*/ 0.13                 \*\*/ 5.98   N.S
            12.72       250.1205           C~14~H~18~O~4~                                  Ubiquinone (HMDB)                              \*\*/ 0.27                 \*\*/ 0.22   \*\*/ 0.06
            14.1        671.489            C~37~H~70~NO~7~P                                Phosphatidylethanolamine (KEGG)                \*\*/ 0                    N.S          \*\*/ 0
            14.3        714.5223           C~47~H~70~O~5~                                  Diacylglycerol (HMDB)                          \*\*/ 0                    N.S          \*\*/ 0
            14.7        571.3638           C~30~H~54~NO~7~P                                1-Acyl-sn-glycerol-3-phosphocholine (HMDB)     \*\*/ 2.02                 \*/ 0.88     \*/ 1.78
            16.4        103.0997           C~5~H~13~NO                                     Choline (HMDB)                                 \*\*/ 1.69                 \*\*/ 0.69   \*/ 1.17
            17.8        522.3604           C~28~H~50~N~4~O~3~S                             Oleic acid (HMDB)                              \*\*/ 0                    N.S          \*\*/ 0
                                                                                                                                                                                  
            1.5         146.1055           C~6~H~14~N~2~O~2~                               L-Lysine (HMDB)                                \*\*/ 1.56                 \*\*/ 1.48   \*\*/ 2.02
            1.6         336.0484           C~11~H~15~NO~9~P                                Nicotinate D-ribonucleotide (HMDB)             \*\*/ 2.58                 N.S          \*\*/ 2.73
            1.8         131.0695           C~4~H~9~N~3~O~2~                                Creatine (HMDB)                                \*\*/ 0.43                 \*\*/ 2.08   N.S
            2.1         119.0582           C~4~H~9~NO~3~                                   L-Threonine (HMDB)                             \*\*/ 0.46                 \*\*/ 2.07   N.S
            4.28        366.0577           C~10~H~15~N~4~O~9~P                             FAICAR (ChemSpider)                            \*\*/ 16.24                \*\*/ 0.04   N.S
            4.29        104.0473           C~4~H~8~O~3~                                    (S)-3-Hydroxy-2-methylpropanoic acid (HMDB)    \*\*/ 1.77                 \*\*/ 0.54   N.S
            5.4         165.0426           C~8~H~7~NO~3~                                   2-(Formylamino)-benzoic acid (HMDB)            \*/ 2.08                   \*\*/ 0.35   N.S
            5.6         180.0786           C~10~H~12~O~3~                                  Coniferyl alcohol (HMDB)                       \*\*/ ∞                    \*\*/ 0      N.S
  ESI (−)   6.5         258.1106           C~8~H~21~NO~6~P                                 sn-glycero-3-Phosphocholine (HMDB)             \*\*/ 0.26                 \*/ 7.93     N.S
            8.0         248.1161           C~13~H~16~N~2~O~3~                              6-Hydroxymelatonin (ChemSpider)                \*\*/ 0.18                 \*/ 4.25     N.S
            10.0        276.1321           C~11~H~20~N~2~O~6~                              Saccharopine (HMDB)                            \*\*/ ∞                    \*\*/ 0.24   \*\*/ ∞
            10.8        324.0359           C~9~H~13~N~2~O~9~P                              Pseudouridylic acid (ChemSpider)               \*\*/ ∞                    \*\*/ 0      N.S
            12.8        308.041            C~9~H~13~N~2~O~8~P                              dUMP (HMDB)                                    \*\*/ 26.7                 \*\*/ 0.1    \*/ 46.8
            15.0        364.2613           C~22~H~36~O~4~                                  Prostaglandin E2 (HMDB)                        \*\*/ 2.10                 N.S          \*\*/ 1.83
            16.6        226.1933           C~14~H~26~O~2~                                  9Z-Tetradecenoic acid (HMDB)                   \*\*/ 0.49                 N.S          \*\*/ 0.47

G1: healthy control group; G2: HFMD group; G3: combination therapy group; HMDB: Human Metabolome Database; KEGG: Kyoto Encyclopedia of Genes and Genomes. (*∞*: represented denominator is zero;  \**P* \< 0.05;  \*\**P* \< 0.01; N.S: no significance).

[^1]: Academic Editor: Wei Jia
